28008-55-1|Daunorubicinol|(8S,10S)-10-(((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-((S)-1-hydroxyethyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione|-范德生物科技公司

Daunorubicinol

NMR下载 COA and HPLC MSDS下载
names：
(8S,10S)-10-(((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-((S)-1-hydroxyethyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione
CAS号：
28008-55-1
MDL Number：
MF(分子式)： C27H31NO10 MW(分子量)： 529.54
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Daunorubicinol
英文别名	Daunorubicinol; Duborimycin; Antibiotic 20-798RP;
CAS号	28008-55-1
Inchi	InChI=1S/C27H31NO10/c1-10-22(30)14(28)7-17(37-10)38-16-9-27(35,11(2)29)8-13-19(16)26(34)21-20(24(13)32)23(31)12-5-4-6-15(36-3)18(12)25(21)33/h4-6,10-11,14,16-17,22,29-30,32,34-35H,7-9,28H2,1-3H3/t10-,11-,14-,16-,17-,22+,27-/m0/s1
InchiKey	HJEZFVLKJYFNQW-PRFXOSGESA-N
分子式 Formula	C27H31NO10
分子量 Molecular Weight	529.54
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Daunorubicinol(CAS:28008-55-1):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Daunorubicinol is the main metabolite of daunomycin.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Cusack BJ, Young SP, Vestal RE, Olson RD. Age-related pharmacokinetics of daunorubicin and daunorubicinol following intravenous bolus daunorubicin administration in the rat. Cancer Chemother Pharmacol. 1997;39(6):505-12. PubMed PMID: 9118462.

[2]Cusack BJ, Young SP, Olson RD. Daunorubicin and daunorubicinol pharmacokinetics in plasma and tissues in the rat. Cancer Chemother Pharmacol. 1995;35(3):213-8. PubMed PMID: 7805179.

[3] Platel D, Bonoron-Adèle S, Robert J. Role of daunorubicinol in daunorubicin-induced cardiotoxicity as evaluated with the model of isolated perfused rat heart. Pharmacol Toxicol. 2001 May;88(5):250-4. PubMed PMID: 11393585.

[4] Callies S, de Alwis DP, Mehta A, Burgess M, Aarons L. Population pharmacokinetic model for daunorubicin and daunorubicinol coadministered with zosuquidar.3HCl (LY335979). Cancer Chemother Pharmacol. 2004 Jul;54(1):39-48. Epub 2004 Mar 24. PubMed PMID: 15045528.

[5] Gewirtz DA, Yanovich S. Metabolism of the anthracycline antibiotic daunorubicin to daunorubicinol and deoxydaunorubicinol aglycone in hepatocytes isolated from the rat and the rabbit. Biochem Pharmacol. 1986 Nov 15;35(22):4059-64. PubMed PMID: 3778526.

6: Cusack BJ, Mushlin PS, Voulelis LD, Li X, Boucek RJ Jr, Olson RD. Daunorubicin-induced cardiac injury in the rabbit: a role for daunorubicinol? Toxicol Appl Pharmacol. 1993 Feb;118(2):177-85. PubMed PMID: 8441996.7: Olson RD, Li X, Palade P, Shadle SE, Mushlin PS, Gambliel HA, Fill M, Boucek RJ Jr, Cusack BJ. Sarcoplasmic reticulum calcium release is stimulated and inhibited by daunorubicin and daunorubicinol. Toxicol Appl Pharmacol. 2000 Dec 1;169(2):168-76. PubMed PMID: 11097869.8: Hoefer CC, Blair RH, Blanco JG. Development of a CART Model to Predict the Synthesis of Cardiotoxic Daunorubicinol in Heart Tissue Samples From Donors With and Without Down Syndrome. J Pharm Sci. 2016 Jun;105(6):2005-2008. doi: 10.1016/j.xphs.2016.03.013. Epub 2016 Apr 23. PubMed PMID: 27112290; PubMed Central PMCID: PMC4885781.9: Hempel G, Relling MV, de Rossi G, Stary J, De Lorenzo P, Valsecchi MG, Barisone E, Boos J, Pieters R. Pharmacokinetics of daunorubicin and daunorubicinol in infants with leukemia treated in the interfant 99 protocol. Pediatr Blood Cancer. 2010 Mar;54(3):355-60. doi: 10.1002/pbc.22266. PubMed PMID: 19731319.10: Slupe A, Williams B, Larson C, Lee LM, Primbs T, Bruesch AJ, Bjorklund C, Warner DL, Peloquin J, Shadle SE, Gambliel HA, Cusack BJ, Olson RD, Charlier HA Jr. Reduction of 13-deoxydoxorubicin and daunorubicinol anthraquinones by human carbonyl reductase. Cardiovasc Toxicol. 2005 Fall;5(4):365-76. PubMed PMID: 16382174.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开